Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Apr 4;216(6):305-311.
doi: 10.5694/mja2.51392. Epub 2022 Feb 9.

Efficacy, safety, and dose-dependence of the analgesic effects of opioid therapy for people with osteoarthritis: systematic review and meta-analysis

Christina Abdel Shaheed  1 , Wasim Awal  2 , Geoffrey Zhang  3 , Stephen E Gilbert  4 , Daniel Gallacher  5 , Andrew McLachlan  1   6 , Richard O Day  7   8 , Giovanni E Ferreira  4 , Caitlin Mp Jones  4 , Harbeer Ahedi  4 , Mamata Tamrakar  4 , Fiona M Blyth  6 , Fiona Stanaway  1 , Christopher G Maher  1   4
Affiliations
Meta-Analysis

Efficacy, safety, and dose-dependence of the analgesic effects of opioid therapy for people with osteoarthritis: systematic review and meta-analysis

Christina Abdel Shaheed et al. Med J Aust. .

Abstract

Objective: To evaluate the efficacy and safety of opioids for analgesic therapy for people with osteoarthritis.

Study design: Systematic review and meta-analysis of randomised, placebo-controlled trials of opioid therapies for treating the pain of osteoarthritis. The primary outcome was medium term pain relief (six weeks to less than 12 months). Quality of evidence was assessed with GRADE criteria.

Data sources: MEDLINE, EMBASE, the Cochrane Database of Systematic Reviews and Central Register of Controlled Trials, CINAHL, PsycINFO, AMED, and the WHO International Clinical Trials Registry; trials published to 31 October 2020.

Data synthesis: We extracted pain, disability, health-related quality of life, and adverse events data for 36 eligible trials (overall dose range: 10-210 oral morphine milligram equivalents [MME] per day). Continuous pain and disability outcomes were converted to common 0-100-point scales; changes of less than ten points were deemed to be very small effects. Differences in dichotomous outcomes were expressed as risk ratios. Data were pooled for meta-analysis in random effects models. The evidence from 19 trials (8965 participants; dose range, 10-126 MME/day) for very small medium term pain relief (mean difference [MD], -4.59 points; 95% CI, -7.17 to -2.02 points) was low quality, as was that from 16 trials (6882 participants; dose range, 10-126 MME/day) for a very small effect on disability (MD, -4.15 points; 95% CI, -6.94 to -1.35 points). Opioid dose was not statistically significantly associated with either degree of pain relief or incidence of adverse events in a meta-regression analysis. Evidence that opioid therapy increased the risk of adverse events (risk ratio, 1.43; 95% CI, 1.29-1.59) was of very low quality.

Conclusions: Opioid medications may provide very small pain and disability benefits for people with osteoarthritis, but may also increase the risk of adverse events.

Prospero registration: CRD42019142813 (prospective).

Keywords: Acute pain; Analgesics, opioid; Arthritis; Chronic pain; Musculoskeletal Pain; Osteoarthritis; Pain management; Systematic review.

PubMed Disclaimer

References

    1. Hunter DJ, March L, Chew M. Osteoarthritis in 2020 and beyond: a Lancet Commission. Lancet 2020; 396: 1711-1712.
    1. Nelson AE, Allen KD, Golightly YM, et al. A systematic review of recommendations and guidelines for the management of osteoarthritis: the chronic osteoarthritis management initiative of the US bone and joint initiative. Semin Arthritis Rheum 2014; 43: 701-712.
    1. Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) 2020; 72: 149-162.
    1. Jevsevar DS. Treatment of osteoarthritis of the knee: evidence-based guideline. J Am Acad Orthop Surg 2013; 21: 571-576.
    1. Huizinga JSE, Song S, Sullivan J, et al. Direct medical and societal cost of opioid use in symptomatic knee osteoarthritis patients in the United States [abstract]. Arthritis Rheumatol 2019; 71 (Suppl 10): abstract 1129.

Substances

LinkOut - more resources